A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
Latest Information Update: 20 Feb 2025
Price :
$35 *
At a glance
- Drugs AZD 4604 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ARTEMISIA
- Sponsors AstraZeneca
- 17 Dec 2024 Planned End Date changed from 12 Aug 2026 to 17 Jul 2026.
- 17 Dec 2024 Planned primary completion date changed from 12 Aug 2026 to 17 Jul 2026.
- 04 Sep 2024 Planned End Date changed from 22 Jul 2026 to 12 Aug 2026.